» Articles » PMID: 31821352

Isobaric Mass Tagging and Triple Quadrupole Mass Spectrometry to Determine Lipid Biomarker Candidates for Alzheimer's Disease

Overview
Journal PLoS One
Date 2019 Dec 11
PMID 31821352
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The isobaric tagging method widely used in proteomic and lipidomic fields, with the multiple reaction monitoring (MRM) approach using a triple quadrupole mass spectrometer, was applied to identify biomarker candidates from plasma samples for Alzheimer's disease (AD). We focused on the following phospholipids that have amino groups as the functional group: phosphatidylethanolamine (PE), Lyso-PE, phosphatidylserine, and Lyso-phosphatidylserine. We also investigated fatty acids that have a carboxy group. A sixplex tandem mass tag (TMT) was used for the isobaric tagging method in this study. The TMT reaction had high reproducibility in human plasma. A total of 196 human plasma samples from three AD cohorts were used for the study, and compared to pooled plasma quality control (QC) samples. The described method required only 40 MRM measurements, including the pooled QC samples, for a full comparison of the data. We found that the content of free fatty acids increased in AD samples in all the three cohorts, alkenyl PEs (ePEs) decreased over a one-year interval in AD patients, and ePEs weakly correlated with amyloid peptide (a-beta) 1-42 in cerebrospinal fluid. In conclusion, total free fatty acids in plasma are a risk factor for AD, and ePEs monitor candidates for AD. Therefore, TMT-lipidomics is a powerful approach for the determination of plasma biomarkers because of the high sample throughput.

Citing Articles

Glial Biologist's Guide to Mass Spectrometry-Based Lipidomics: A Tutorial From Sample Preparation to Data Analysis.

Randolph C, Walker K, Yu R, Beveridge C, Manchanda P, Chopra G Glia. 2025; 73(3):474-494.

PMID: 39751169 PMC: 11784846. DOI: 10.1002/glia.24665.


Lipid Isobaric Mass Tagging for Enhanced Relative Quantification of Unsaturated -Positional Isomers.

Yang T, Tang S, Feng J, Yan X ACS Meas Sci Au. 2024; 4(2):213-222.

PMID: 38645577 PMC: 11027206. DOI: 10.1021/acsmeasuresciau.3c00062.


Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment.

Nie Y, Chu C, Qin Q, Shen H, Wen L, Tang Y Brain Pathol. 2023; 34(1):e13202.

PMID: 37619589 PMC: 10711261. DOI: 10.1111/bpa.13202.


Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias.

Yassine H, Self W, Kerman B, Santoni G, Navalpur Shanmugam N, Abdullah L Alzheimers Dement. 2022; 19(3):1041-1066.

PMID: 36479795 PMC: 10576546. DOI: 10.1002/alz.12845.


The Second Asia-Oceania Human Proteome Organization (AOHUPO) Online Education Series on the Renaissance of Clinical Proteomics: Biomarkers, Imaging and Therapeutics.

Low T, Chen Y, Ishihama Y, Chung M, Cordwell S, Poon T Mol Cell Proteomics. 2022; 21(12):100436.

PMID: 36309314 PMC: 9700300. DOI: 10.1016/j.mcpro.2022.100436.


References
1.
Mapstone M, Cheema A, Fiandaca M, Zhong X, Mhyre T, MacArthur L . Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8. PMC: 5360460. DOI: 10.1038/nm.3466. View

2.
Sun F, Choi A, Wu R . Systematic Analysis of Fatty Acids in Human Cells with a Multiplexed Isobaric Tag (TMT)-Based Method. J Proteome Res. 2018; 17(4):1606-1614. PMC: 5937127. DOI: 10.1021/acs.jproteome.7b00896. View

3.
Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

4.
Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y . Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res. 2011; 53(3):567-576. PMC: 3276481. DOI: 10.1194/jlr.M022376. View

5.
Wood P, Mankidy R, Ritchie S, Heath D, Wood J, Flax J . Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci. 2009; 35(1):59-62. PMC: 2799506. DOI: 10.1503/jpn.090059. View